Drug Trial Radar · NCT02132000
Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients
Last checked: Nov 19, 2026Latest source record: May 6, 2014 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Status unknown
Enrollment
3,036
Planned (sponsor's estimate)
Start
Apr 2014
Primary completion
May 2020
Study completion May 2020
Sponsor
- Lead sponsor
- Fengxi SuAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- May 6, 2014
Design
- Study type
- Interventional
- Phase
- Phase 2 / Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- Who can join
- Female only, from 18 years, up to 60 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
In premenopausal women, endocrine adjuvant therapy for breast cancer primarily consists of tamoxifen alone or with ovarian suppressive strategies. Toremifene is a chlorinated derivative of tamoxifen, but with a superior risk-benefit profile. In this trial, we sought to compare the efficacy and tolerability of toremifene and tamoxifen therapy in premenopausal patients with operable,estrogen and/or progesterone receptor positive breast cancer patients.
Conditions
- Breast Cancer Patients in Premenopausal
- Estrogen and/or Progesterone Receptor Positive
Interventions
toremifene or tamoxifenDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- survival outcomes: disease free survivalTime frame: up to 5 years
- 5-year overall survivalTime frame: up to 5 years
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Breast cancer center of Sun Yat-sen Memorial Hospital
Guangzhou, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.